GRTS Investors Have Opportunity to lead Gritstone bio, Inc. Securities Fraud Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Gritstone bio, Inc. for allegedly making false and misleading statements regarding its COVID-19 vaccine candidate and its ability to launch the Phase 2b CORAL Study, which has negatively impacted investors [6][9]. Group 1: Lawsuit Details - The lawsuit claims that Gritstone misrepresented its timeline for launching the Phase 2b CORAL Study, which compares its COVID-19 vaccine candidate with an approved vaccine [6]. - It is alleged that Gritstone's inability to launch the study would impair its ability to secure external funding, affecting its financial stability [6]. - The lawsuit asserts that Gritstone overstated its capability to develop and commercialize its products, leading to materially false and misleading public statements [6]. Group 2: Class Action Participation - Investors who purchased Gritstone securities during the Class Period from March 9, 2023, to February 29, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [5][9]. - Interested parties can join the class action by submitting a form or contacting the law firm for more information [2][3].